CyPass® Micro-Stent
2017 Coding and Billing Guide

CyPass® Micro-Stent Description and Indication

The CyPass® Micro-Stent received FDA approval on July 29, 2016. The CyPass® System is indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild to moderate primary open-angle glaucoma (POAG).¹

Procedure and Device Coding

The CyPass® Micro-Stent should be reported using Current Procedural Terminology (CPT®) Code 0474T; insertion of anterior segment aqueous drainage device, with creation of intraocular reservoir, internal approach, into the supraciliary space. The applicable cataract procedure code should also be reported.

Facility claims require a Healthcare Common Procedure Coding System (HCPCS) code to identify the implant. The most common HCPCS codes used to report the CyPass® Micro-Stent implant are C1783, ocular implant, aqueous drainage assist device, or L8612, aqueous shunt. Failure to include the HCPCS code that describes the CyPass® device may result in inaccurate payment.

Common Coding for Physicians and Facilities

<table>
<thead>
<tr>
<th>Physician</th>
<th>Ambulatory Surgery Center, Freestanding</th>
<th>Hospital Outpatient Department</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. 0474T; insertion of anterior segment aqueous drainage device, with creation of intraocular reservoir, internal approach, into the supraciliary space</td>
<td>1. 0474T; insertion of anterior segment aqueous drainage device, with creation of intraocular reservoir, internal approach, into the supraciliary space and associated revenue code</td>
<td>1. 0474T; insertion of anterior segment aqueous drainage device, with creation of intraocular reservoir, internal approach, into the supraciliary space and associated revenue code</td>
</tr>
<tr>
<td>3. Either C1783, ocular implant, aqueous drainage assist device, or L8612, aqueous shunt</td>
<td>3. Either C1783, ocular implant, aqueous drainage assist device, or L8612, aqueous shunt with revenue code 0278, other implants</td>
<td>3. Either C1783, ocular implant, aqueous drainage assist device, or L8612, aqueous shunt with revenue code 0278, other implants</td>
</tr>
</tbody>
</table>

Note: This is not an inclusive list of codes. An example of a physician services claim form is available on page 3.

Note: This is not an inclusive list of codes. An example of a freestanding ambulatory surgery center claim form is available on page 4.

Note: This is not an inclusive list of codes. An example of a hospital outpatient claim form is available on page 5.

¹The most common cataract CPT code is 66984; Extracapsular cataract removal with insertion of intraocular lens prosthesis (one stage procedure), manual or mechanical technique (e.g. irrigation and aspiration or phacoemulsification), however other codes may apply.

1. See the back page for Important Safety Information. 2. CPT® is a registered trademark of the American Medical Association.
**Diagnosis Coding**

Diagnosis coding is determined by the patient’s condition. The ICD-10-CM codes listed below are commonly associated with patients receiving the CyPass® Micro-Stent. The list below is not intended to provide an exhaustive list of all possible diagnosis codes. **Note that in all cases, it is ultimately the responsibility of the provider to report the ICD-10-CM diagnosis code that most accurately describes the patient’s condition.**

The CyPass® Micro-Stent is indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild to moderate primary open-angle glaucoma (POAG).

Common diagnosis codes include:

<table>
<thead>
<tr>
<th>ICD-10-CM</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>H40.1111</td>
<td>Primary open-angle glaucoma, right eye, mild stage</td>
</tr>
<tr>
<td>H40.1112</td>
<td>Primary open-angle glaucoma, right eye, moderate stage</td>
</tr>
<tr>
<td>H40.1121</td>
<td>Primary open-angle glaucoma, left eye, mild stage</td>
</tr>
<tr>
<td>H40.1122</td>
<td>Primary open-angle glaucoma, left eye, moderate stage</td>
</tr>
<tr>
<td>H40.1131</td>
<td>Primary open-angle glaucoma, bilateral, mild stage</td>
</tr>
<tr>
<td>H40.1132</td>
<td>Primary open-angle glaucoma, bilateral, moderate stage</td>
</tr>
</tbody>
</table>

**Coverage**

Some payers have established positive coverage decisions for the implantation of the CyPass® Micro-Stent device. Alcon continues to work with payers to obtain positive coverage and specific guidance for the placement of the CyPass® Micro-Stent.

Payers may require a prior authorization or pre determination and in some cases additional documentation to support the claim.

Contact Alcon Reimbursement Services at (866) 457-0277 or at: ARS.SupportUS@alcon.com with questions about specific coverage policies.

---

This information is provided for informational purposes only. It does not constitute legal or reimbursement advice or recommendations regarding clinical practice. Alcon makes no guarantee that use of this information will result in coverage or payment or prevent disagreement by payers with regard to billing, coverage or amount of payment. Alcon encourages providers to submit accurate and appropriate claims for services. It is always the provider’s responsibility to determine medical necessity, the proper site for delivery of any services and to submit accurate information, codes, charges, and modifiers for services that are rendered. Coding, coverage and payment policies are complex and are frequently updated. Alcon recommends that you consult with your legal counsel, applicable payers’ policies or reimbursement specialists regarding coding, coverage and reimbursement.
Box 10: Insert the description of 0474T; "Insertion of aqueous drainage device into the supraciliary space."

Box 21: DIAGNOSIS
Enter applicable diagnosis codes.

Common Place of Service Codes are:
19: Off Campus-Outpatient Hospital
22: On Campus-Outpatient Hospital
24: Ambulatory Surgical Center, Freestanding

This information is provided for informational purposes only. It does not constitute legal or reimbursement advice or recommendations regarding clinical practice. Alcon makes no guarantee that use of this information will result in coverage or payment or prevent disagreement by payers with regard to billing, coverage or amount of payment. Alcon encourages providers to submit accurate and appropriate claims for services. It is always the provider’s responsibility to determine medical necessity, the proper site for delivery of any services and to submit accurate information, codes, charges, and modifiers for services that are rendered. Coding, coverage and payment policies are complex and are frequently updated. Alcon recommends that you consult with your legal counsel, applicable payers’ policies or reimbursement specialists regarding coding, coverage and reimbursement.
When using a UB-04, refer to the Hospital Outpatient Claim Form Example.

Insertion of aqueous drainage device into the supraciliary space

Box 19: Insert the description of 0474T; “Insertion of an anterior segment aqueous drainage device, into the supraciliary space.”

Box 21: DIAGNOSIS
Enter applicable diagnosis codes.

Box 24D: Report the CyPass® device with C1783, ocular implant, aqueous drainage assist device, or L8612, aqueous shunt. Failure to report the device may result in inaccurate payment.

Alcon Reimbursement Services (866) 457-0277

This information is provided for informational purposes only. It does not constitute legal or reimbursement advice or recommendations regarding clinical practice. Alcon makes no guarantee that use of this information will result in coverage or payment or prevent disagreement by payers with regard to billing, coverage or amount of payment. Alcon encourages providers to submit accurate and appropriate claims for services. It is always the provider’s responsibility to determine medical necessity, the proper site for delivery of any services and to submit accurate information, codes, charges, and modifiers for services that are rendered. Coding, coverage and payment policies are complex and are frequently updated. Alcon recommends that you consult with your legal counsel, applicable payers’ policies or reimbursement specialists regarding coding, coverage and reimbursement.
Example Hospital Outpatient Claim Form for the CyPass® Micro-Stent

**Box 42: REVENUE CODE**
Use revenue code 0278, other implants, for the CyPass® device.

**Box 44: HCPCS CODE**
Report the CyPass® device with C1783, ocular implant, aqueous drainage assist device, or L8612, aqueous shunt. Failure to report the device may result in inaccurate payment.

**Box 66: DIAGNOSIS**
Enter applicable diagnosis codes.

**Box 80: REMARKS**
Insert the description of the HCPCS Code for the intraocular lens.
Example:
Line 3: Insertion of a posterior chamber intraocular lens (V2632).

**Box 80: REMARKS**
Insert the description of the HCPCS Code for the aqueous drainage device.
Example:
Line 6: Insertion of an anterior segment aqueous drainage device into the supraciliary space (C1783 or L8612).

Alcon Reimbursement Services  (866) 457- 0277
CyPass® Micro-Stent
Important Product Information

Caution:
Federal (USA) law restricts this device to sale by or on the order of a physician.

Indication:
The CyPass® Micro-Stent is indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild to moderate primary open-angle glaucoma (POAG).

Contraindications:
Use of the CyPass® Micro-Stent is contraindicated in the following circumstances or conditions: (1) in eyes with angle closure glaucoma; and (2) in eyes with traumatic, malignant, uveitic or neovascular glaucoma or discernible congenital anomalies of the anterior chamber angle.

MRI Information:
The CyPass® Micro-Stent is magnetic resonance (MR) Safe: the implant is constructed of polyimide material, a non-conducting, non-metallic, non-magnetic polymer that poses no known hazards in all magnetic resonance imaging environments.

Warnings:
Gonioscopy should be performed prior to surgery to exclude peripheral anterior synechiae (PAS), rubeosis, and other angle abnormalities or conditions that would prohibit adequate visualization of the angle that could lead to improper placement of the stent and pose a hazard.

Precautions:
The surgeon should monitor the patient postoperatively for proper maintenance of intraocular pressure. The safety and effectiveness of the CyPass® Micro-Stent has not been established as an alternative to the primary treatment of glaucoma with medications, in patients 21 years or younger, in eyes with significant prior trauma, chronic inflammation, eyes with an abnormal anterior segment, eyes with chronic inflammation, eyes with glaucoma associated with vascular disorders, pseudophakic eyes with glaucoma, eyes with uveitic glaucoma, eyes with pseudoexfoliative or pigmentary glaucoma, eyes with other secondary open angle glaucomas, eyes that have undergone prior incisional glaucoma surgery or cilioablatiave procedures, eyes with laser trabeculoplasty performed ≤ 3 months prior to the surgical screening visit, eyes with unmedicated IOP less than 21 mmHg or greater than 33 mmHg, eyes with medicated IOP greater than 25 mmHg, in the setting of complicated cataract surgery with iatrogenic injury to the anterior or posterior segment, and when implantation is without concomitant cataract surgery with IOL implantation for visually significant cataract. The safety and effectiveness of use of more than a single CyPass® Micro-Stent has not been established.

Adverse Events:
In a randomized, multicenter clinical trial comparing cataract surgery with CyPass® to cataract surgery alone, the most common post-operative adverse events included: BCVA loss of 10 or more letters at 3 months after surgery (8.8% for CyPass vs. 15.3% for cataract surgery only); anterior chamber cell and flare requiring steroid treatment 30 or more days after surgery (8.6% vs. 3.8%); worsening of visual field mean deviation by 2.5 or more decibels (6.7% vs. 9.9%); IOP increase of 10 or more mmHg 30 or more days after surgery (4.3% vs. 2.3%); and corneal edema 30 or more days after surgery, or severe in nature (3.5% vs. 1.5%).

Attention:
Please refer to the Product Instructions for a complete list of contraindications, warnings, precautions and adverse events.